| Previous Close | 0.8164 |
| Open | 0.8142 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.7793 - 0.8500 |
| 52 Week Range | 0.0855 - 1.2587 |
| Volume | 26,690 |
| Avg. Volume | 24,096 |
| Market Cap | 59.346M |
| Beta (5Y Monthly) | 3.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Core One Labs Completes Sale of Non-Core Assets
VANCOUVER, BC / ACCESSWIRE / January 15, 2021 /Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,000,000 plus the assumption of approximately USD$4,000,000 in related liabilities.
- ACCESSWIRE
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
VANCOUVER, BC / ACCESSWIRE / January 12, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company") is pleased to announce its plans to initiate another intellectual property strategy that will utilize its patented transmucosal thinstrip delivery method ("thinstrip delivery method") in combination with its proprietary biosynthetic psilocybin, developed by its wholly-owned subsidiary, Vocan Biotechnologies Inc.
- ACCESSWIRE
Leading Microbiologist, Dr. Robert E.W. Hancock Appointed as Executive Chairman of Core One Labs
VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Core One Labs Inc.
